Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:47 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 856 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: HER-2 Positive Breast Cancer Clear all

Conditions: Breast Cancer Female, Breast Cancer, Male, Breast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage III, Residual Disease, HER2-positive Breast Cancer, HER2 Positive Breast Carcinoma
Interventions: DC1 Vaccine, WOKVAC Vaccine; Biological
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 7
States / cities: Tampa, Florida • Atlanta, Georgia • Indianapolis, Indiana + 4 more

Conditions: Breast Neoplasms
Interventions: Radium-223 dichloride (Xofigo, BAY88-8223), Placebo (saline), Background hormonal therapy; Drug · Other
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 11
States / cities: Bakersfield, California • La Jolla, California • Aurora, Colorado + 8 more

Conditions: HER2 Expressing Solid Tumors
Interventions: Dose Level 1, VNX-202, Dose Level 2, VNX-202, Dose Level 3, VNX-202, Dose Level 4, VNX-202; Genetic
Lead sponsor: Vironexis Biotherapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2033
U.S. locations: 11
States / cities: Los Angeles, California • Denver, Colorado • Jacksonville, Florida + 8 more

Conditions: Stage IV (Metastatic) Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer, PR-Positive Breast Cancer, HER2-negative Breast Cancer, Invasive Breast Cancer
Interventions: NERATINIB, FULVESTRANT; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 2
States / cities: Boston, Massachusetts • Nashville, Tennessee

Conditions: Anatomic Stage IV Breast Cancer AJCC v8, HER2 Positive Breast Carcinoma, Metastatic Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8
Interventions: Abemaciclib, Trastuzumab Emtansine; Drug · Biological
Lead sponsor: Academic and Community Cancer Research United; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 6
States / cities: Yuma, Arizona • Jacksonville, Florida • Urbana, Illinois + 3 more

Conditions: Breast Cancer
Interventions: Abemaciclib, Letrozole; Drug
Lead sponsor: Mridula George, MD; Other
Eligibility: 60 Years and older · Female only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2032
U.S. locations: 4
States / cities: Belleville, New Jersey • Livingston, New Jersey • New Brunswick, New Jersey + 1 more

Conditions: Breast Cancer
Interventions: Arm A: Gedatolisib + Palbociclib + Fulvestrant, Arm B: Ribociclib + Fulvestrant, Arm C: Gedatolisib + Palbociclib + Letrozole, Arm D: Ribociclib + Letrozole; Drug
Lead sponsor: Celcuity Inc; Industry
Eligibility: 18 Years and older
Enrollment: 1,180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2033
U.S. locations: 30
States / cities: Jonesboro, Arkansas • Little Rock, Arkansas • Duarte, California + 27 more

Conditions: Breast Neoplasms
Interventions: Imlunestrant, Goserelin, Tamoxifen 20 mg; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 37
States / cities: Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 29 more

Conditions: Breast Cancer
Interventions: Elacestrant, Onapristone; Drug
Lead sponsor: Context Therapeutics Inc.; Industry
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Early Breast Cancer
Interventions: Ribociclib, Endocrine Therapy (ET); Drug · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 5,101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2030
U.S. locations: 73
States / cities: Birmingham, Alabama • Goodyear, Arizona • Jonesboro, Arkansas + 68 more

Conditions: Breast Neoplasms
Interventions: PF-06804103, PF-06804103 + Palbociclib +Letrozole; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 26
States / cities: Tucson, Arizona • Los Angeles, California • Santa Monica, California + 14 more

Conditions: Metastatic Breast Cancer
Interventions: DB-1303/BNT323, Capecitabine, Paclitaxel, Nab-paclitaxel; Drug
Lead sponsor: DualityBio Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 541 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 44
States / cities: Tucson, Arizona • Fullerton, California • Los Angeles, California + 39 more

Conditions: Breast Cancer
Interventions: Breast surgery; Procedure
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 10
States / cities: Hartford, Connecticut • Ann Arbor, Michigan • Basking Ridge, New Jersey + 7 more

Conditions: Metastatic Hormone-Receptor-Positive (HR+) Breast Cancer, HER2-Negative Breast Cancer, Metastatic Epithelial Ovarian Cancer
Interventions: Ribociclib, PDR001, Fulvestrant; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 3
States / cities: Boston, Massachusetts

Conditions: HER2-positive Breast Cancer
Interventions: [18F]FMISO PET/MRI imaging; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older · Female only
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Breast Cancer
Interventions: Atezolizumab, Placebo, Doxorubicin, Cyclophosphamide, Paclitaxel, Trastuzumab, Pertuzumab, Trastuzumab Emtansine; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 454 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 3
States / cities: Kansas City, Missouri • New York, New York • Nashville, Tennessee

Conditions: Breast Cancer
Interventions: Inavolisib, Fulvestrant; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 4
States / cities: Los Angeles, California • Jacksonville, Florida • Kansas City, Missouri + 1 more

Conditions: Breast Cancer, ER Positive Breast Cancer, HER2-negative Breast Cancer, TNBC - Triple-Negative Breast Cancer
Interventions: Collection of personal health information from women treated at the University of Pennsylvania under an approved HIPAA waiver.; Other
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older · Female only
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2032
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Neoplasms
Interventions: GSK525762, Placebo, Fulvestrant; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 15
States / cities: Birmingham, Alabama • Gilbert, Arizona • Scottsdale, Arizona + 12 more

Conditions: HER2-positive Breast Cancer, Metastatic Breast Cancer
Interventions: Pertuzumab, Trastuzumab, eribulin; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Breast Cancer
Interventions: DS-8201a; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 253 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 36
States / cities: Anchorage, Alaska • Tucson, Arizona • Los Angeles, California + 26 more

Conditions: Triple Negative Breast Cancer, HER2-negative Breast Cancer
Interventions: HER2 - primed Dendritic cells, HER3 - primed Dendritic cells; Biological
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Breast Cancer
Interventions: Dato-DXd, Capecitabine, Gemcitabine, Eribulin, Vinorelbine; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 732 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 14
States / cities: Duarte, California • Los Angeles, California • Palo Alto, California + 10 more

Conditions: Metastatic Breast Cancer
Interventions: Sacituzumab Govitecan-hziy, Eribulin, Capecitabine, Gemcitabine, Vinorelbine; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 543 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 55
States / cities: Avondale, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 40 more

Search by objective public record fields.

Vaccine to Prevent Recurrence in Patients With HER-2 Positive Breast Cancer

Study of Radium-223 Dichloride Versus Placebo and Hormonal Treatment as Background Therapy in Subjects With Bone Predominant HER2 (Human Epidermal Growth Factor Receptor 2) Negative Hormone Receptor Positive Metastatic Breast Cancer

Gene Therapy for HER-Positive Cancer (SENTRY-HER2)

Fulvestrant + Neratinib In Breast Cancer

T-DM1 With or Without Abemaciclib for the Treatment of HER2-Positive Metastatic Breast Cancer

RADIANT: Pre-op Radiation With Abemaciclib and Letrozole

Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)

A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer

A Rollover Protocol of Elacestrant, in Combination With Onapristone, for Patients With ER+, PR+, HER2- Advanced or Metastatic Breast Cancer

A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer

PF-06804103 Dose Escalation in HER2 Positive and Negative (Negative Only in Part 2) Solid Tumors

A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)

Use of Sentinel Lymph Node Biopsy in Patients With Early-Stage, Palpable Node-Positive HR+/HER2- Breast Cancer Having Upfront Surgery and Adjuvant Radiation

Ribociclib + PDR001 in Breast Cancer and Ovarian Cancer

Monitoring HER2+ Breast Cancer Neoadjuvant Treatment With Advanced PET/MRI

A Study To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer

To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer

Role of the Immune Environment in Response to Therapy in Breast Cancer

Dose Escalation and Expansion Study of GSK525762 in Combination With Fulvestrant in Participants With Hormone Receptor-positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Advanced or Metastatic Breast Cancer

Phase II Study of Eribulin Mesylate, Trastuzumab, and Pertuzumab in Women With Metastatic, Unresectable Locally Advanced, or Locally Recurrent HER2-Positive Breast Cancer

A Study of DS-8201a in Metastatic Breast Cancer Previously Treated With Trastuzumab Emtansine (T-DM1)

DecipHER Trial - DC1 Tx for Early-Stage TNBC and ER Low Positive Breast Cancer

A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)

Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Participants With HR+/HER2- Metastatic Breast Cancer